Cargando…
Effect of Ethanol on the Metabolic Characteristics of HIV-1 Integrase Inhibitor Elvitegravir and Elvitegravir/Cobicistat with CYP3A: An Analysis Using a Newly Developed LC-MS/MS Method
Elvitegravir (EVG), an integrase inhibitor for the treatment HIV infection, is increasingly becoming the part of first-line antiretroviral therapy (ART) regimen. EVG is mainly metabolized through cytochrome P450 (CYP) 3A4. Previously, we have shown that ethanol alters ART-CYP3A4 interactions with pr...
Autores principales: | Midde, Narasimha M., Rahman, Mohammad A., Rathi, Chetan, Li, Junhao, Meibohm, Bernd, Li, Weihua, Kumar, Santosh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4752462/ https://www.ncbi.nlm.nih.gov/pubmed/26872388 http://dx.doi.org/10.1371/journal.pone.0149225 |
Ejemplares similares
-
Alterations in cellular pharmacokinetics and pharmacodynamics of elvitegravir in response to ethanol exposure in HIV-1 infected monocytic (U1) cells
por: Midde, Narasimha M., et al.
Publicado: (2017) -
Novel elvitegravir nanoformulation approach to suppress the viral load in HIV-infected macrophages
por: Gong, Yuqing, et al.
Publicado: (2017) -
Efficacy, safety, and patient acceptability of elvitegravir/cobicistat/emtricitabine/tenofovir in the treatment of HIV/AIDS
por: Prinapori, Roberta, et al.
Publicado: (2015) -
An indirect comparison of efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir and dolutegravir + abacavir/lamivudine
por: Rogatto, Felipe, et al.
Publicado: (2014) -
Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors
por: Serrao, Erik, et al.
Publicado: (2009)